NTRA delivered a blowout Q2 print on August 6, rocketing 21% in a single session to $322 — and the consensus is still running behind the stock.
The analyst response has been swift and unanimous. Every firm with a recent rating move has lifted its target, with no downgrades or holds introduced. JPMorgan's Casey Woodring raised the Overweight target to $360 from $315 on August 7. RBC Capital went further, bumping its Outperform target to $350 from $275 — the most aggressive revision in the cohort. Evercore ISI Group lifted to $360, TD Cowen to $340, and Citigroup to $315. The mean price target now sits at roughly $313, which the stock has already eclipsed at $322. That gap matters: the Street was collectively underweight the move, and targets are still being calibrated upward. The one outlier in tone is Wells Fargo, which nudged its Equal-Weight target to $284 from $220 — still constructive on the revision, but explicitly not endorsing the current price level.
The positioning picture is the inverse of what was described in the pre-earnings note filed two days ago. Options had been flagging unusual defensiveness, with the put/call ratio running more than two standard deviations above its 20-day average heading into the print. Post-earnings, that caution looks like it amplified the move: the PCR hit 1.04 on August 7 — its highest reading in weeks — suggesting some of the protective put positioning is now being unwound or rolled. Short interest, at 3.5% of the float, fell roughly 11% from its mid-July peak of around 5.6% and has been grinding quietly lower since late July. Shorts covered before the print, not after it. The borrow market remains trivially loose: availability of over 8,000% confirms there is no meaningful short-side pressure in the lending pool, and the cost to borrow, while nearly doubling over the past week to 0.54%, is still negligible in absolute terms.
Insiders were selling into the strength. On August 3 — before the print — CEO Steven Chapman, CFO Michael Brophy, and two division presidents all filed small sales, ranging from 70 to 1,233 shares at prices in the $261–$268 range. These are low-significance, routine-looking transactions — significance scores of 1-2 — consistent with pre-programmed 10b5-1 plans rather than a directional signal. The 90-day net insider flow is actually a modest positive at roughly 21,700 net shares acquired, so the picture over a longer window looks less uniformly bearish than the near-term sell cluster implies.
The bull-bear debate heading into the print centred on Signatera MRD test penetration rates and whether revenue growth could justify a stretched valuation. The bear case — stalling ASP expansion and premium-to-peers pricing — just got harder to sustain. The price-to-book multiple of 18.6x and a deeply negative PE reflect a company still burning cash, but the EV/EBITDA trend has been improving sharply, compressing by roughly 68 points over the past 30 days. Forward EPS momentum ranks in the 86th percentile of the universe — the growth story is gaining credibility with the Street, not losing it. Peers had a strong week too, but NTRA led: CAI gained 14% on the day and 45% on the week, while TWST added 6% Friday and 26% over five days, suggesting a rising-tide moment for the broader genomics space, not just a NTRA-specific re-rating.
The next earnings event is scheduled for November 6. Between now and then, the question shifts from whether the quarter was good to whether the Street can close the gap between current price and the cluster of targets still sitting at or below $360 — and whether any analyst moves to downgrade on valuation before the next print.
See the live data behind this article on ORTEX.
Open NTRA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
